Unity Biotechnology Inc Market Cap ($2.75 Million)
Market Cap & Net Worth: Unity Biotechnology Inc (UBX)
Unity Biotechnology Inc market cap. Unity Biotechnology Inc (NASDAQ:UBX) has a market capitalization of $2.75 Million ($2.75 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29601 globally and #6049 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Unity Biotechnology Inc's stock price $0.16 by its total outstanding shares 17212200 (17.21 Million). Also see cash efficiency ratio of Unity Biotechnology Inc for how efficiently the company converts equity into cash flow.
Unity Biotechnology Inc Market Cap History (2018–2025)
Unity Biotechnology Inc market cap history from 2018 to 2025. Data shows change from $2.80 Billion to $2.75 Million (-61.96% CAGR). Check Unity Biotechnology Inc share price for real-time trading data and today's change.
Index Memberships
Unity Biotechnology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #851 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2730 of 3165 |
Weight: Unity Biotechnology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Unity Biotechnology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Unity Biotechnology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore UBX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
199.84x
Unity Biotechnology Inc's market cap is 199.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $251.30 Million | $4.78 Million | -$60.04 Million | 52.53x | N/A |
| 2022 | $47.16 Million | $236.00K | -$57.75 Million | 199.84x | N/A |
Competitor Companies of UBX by Market Capitalization
Companies near Unity Biotechnology Inc in the global market cap rankings as of November 4, 2026. Also see UBX total assets for a full breakdown of the balance sheet.
Key companies related to Unity Biotechnology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Unity Biotechnology Inc (2018–2025)
Market capitalization of Unity Biotechnology Inc from 2018 to today. Between 2018 and today, Unity Biotechnology Inc's market cap moved from $2.80 Billion to $ 2.75 Million, with a yearly change of -61.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.75 Million | -83.61% |
| 2024 | $16.81 Million | -49.41% |
| 2023 | $33.22 Million | -29.56% |
| 2022 | $47.16 Million | -81.23% |
| 2021 | $251.30 Million | -72.14% |
| 2020 | $901.92 Million | -27.32% |
| 2019 | $1.24 Billion | -55.66% |
| 2018 | $2.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 8th, 2026 the market cap of Unity Biotechnology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.75 Million USD |
| MoneyControl | $2.75 Million USD |
| MarketWatch | $2.75 Million USD |
| marketcap.company | $2.75 Million USD |
| Reuters | $2.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more